Literature DB >> 23829228

Successful management of severe hemolytic disease of the fetus due to anti-Jsb using intrauterine transfusions with serial maternal blood donations: a case report and a review of the literature.

Arwa Z Al Riyami1, Moza Al Salmani, Sabria Al Hashami, Sabah Al Mahrooqi, Sumaiya Al Hinai, Halima Al Balushi, Nihal Al Riyami, V Gowri, Tamima Al Dughaishi, Saif Al Hosni, Murtadha Al-Khabori, Khalil Al-Farsi, Mohammed Al Huneini, Salam Alkindi.   

Abstract

BACKGROUND: The management of pregnant women with anti-Jsb is challenging due to the paucity of antigen-negative blood for fetal and neonatal transfusion. CASE REPORT: A 29-year-old woman with anti-Jsb was referred for assessment of recurrent fetal losses. With the presence of the sister as a historically matched donor, she was planned for active surveillance for fetal anemia during pregnancy. STUDY DESIGN AND METHODS: The fetus remained well until 21 weeks of gestation when signs of fetal anemia and early hydrops fetalis were noted. Anti-Jsb titer was at 128. The sister's red blood cells (RBCs) were cross-match incompatible. Urgent intrauterine transfusion (IUT) was performed with washed irradiated maternal RBCs, donated after cessation of heparin. The mother was given intravenous iron (IV-Fe) and continued on weekly recombinant human erythropoietin (rHu-EPO).
RESULTS: Repeated IUTs were needed every 1 to 3 weeks. Throughout a 7-week period, three maternal donations were performed with total donated whole blood volume of 1250 mL, supporting four IUTs. At 29 weeks of gestation, the procedure was complicated by umbilical cord hematoma necessitating urgent cesarean section. A male newborn was delivered, transfused at birth, and subsequently treated with phototherapy and five top-up transfusions.
CONCLUSION: This case represents a successful example of managing hemolytic disease of the fetus due to a rare antibody using maternal blood. It also supports previous data on safety of maternal donations during pregnancy and the use of combination of rHu-EPO and IV-Fe as a supportive measure.
© 2013 American Association of Blood Banks.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23829228     DOI: 10.1111/trf.12331

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  3 in total

1.  Intrauterine Fetal Blood Transfusion: Descriptive study of the first four years' experience in Oman.

Authors:  Arwa Z Al-Riyami; Mouza Al-Salmani; Sabria N Al-Hashami; Sabah Al-Mahrooqi; Ali Al-Marhoobi; Sumaiya Al-Hinai; Saif Al-Hosni; Sathiya M Panchatcharam; Zainab A Al-Arimi
Journal:  Sultan Qaboos Univ Med J       Date:  2018-04-04

2.  Frequency of Red Cell Alloantibodies in Pregnant Females of Navsari District: An Experience that Favours Inclusion of Screening for Irregular Erythrocyte Antibody in Routine Antenatal Testing Profile.

Authors:  Manoj Kahar
Journal:  J Obstet Gynaecol India       Date:  2017-03-29

Review 3.  The Outcome of Hemolytic Disease of the Fetus and Newborn Caused by Anti-Rh17 Antibody: Analysis of Three Cases and Review of the Literature.

Authors:  Slavica Dajak; Nina Ipavec; Mia Cuk; Branka Golubic Cepulic; Jela Mratinovic-Mikulandra; Josipa Milardovic; Vedran Stefanovic
Journal:  Transfus Med Hemother       Date:  2019-10-03       Impact factor: 3.747

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.